Fennec announces commercial launch of PEDMARQSI in Germany

Fennec (FENC) Pharmaceuticals announced that Norgine Pharmaceuticals has commercially launched PEDMARQSI in Germany. “Until now, there have been no pharmacological interventions available to cancer patients in Germany to prevent ototoxicity, or permanent hearing loss, caused by treatment with cisplatin,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. “We congratulate Norgine on making PEDMARQSI available to patients and healthcare providers in Germany and look forward to future launches in other major European markets.”